sPD-L1 was the most investigated parameter with 9 reviewed studies focusing on ICI outcomes in NSCLC patients including a cohort of 119 NSCLC patients, with a control group of 29 healthy volunteers (110). This evidence concerns the gene SPDL1 and non-small cell lung carcinoma.